Concepedia

James E. H. Day

JE

Statistics

Publications

12

Citations

520

H-Index

11

Active since

2009

Affiliations

GW Pharmaceuticals (United Kingdom)(Current)

Institute of Cancer Research

University of Nottingham

Cancer Research UK

Signature Research (United States)

James E. H. Day is an author at GW Pharmaceuticals (United Kingdom) specializing in drug discovery, medicinal chemistry, and pharmacology.

ORCID

Publications per year

2009–2024

12

Publications

12

Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP

Gianni Chessari, Ildiko M. Buck, James E. H. Day et al. · Journal of Medicinal Chemistry · 2015 · 86 citations · Full text

, , +17

Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP)

Emiliano Tamanini, Ildiko M. Buck, Gianni Chessari et al. · Journal of Medicinal Chemistry · 2017 · 71 citations · Full text

, , +17

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2

Tom D. Heightman, Valério Berdini, Hannah Braithwaite et al. · Journal of Medicinal Chemistry · 2018 · 66 citations · Full text

, , +16

Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors

Christopher W. Murray, Valério Berdini, Ildiko M. Buck et al. · ACS Medicinal Chemistry Letters · 2015 · 61 citations · Full text

, , +17

The identification of novel PLC-γ inhibitors using virtual high throughput screening

Jóhannes Reynisson, William Court, Ciaran O’Neill et al. · Bioorganic & Medicinal Chemistry · 2009 · 56 citations · Full text

, , +14

1–5 of 12